Merck Announces New Data from Phase 3 Trials Evaluating the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) in Adults with Virologically Suppressed HIV-1 ...

The two-drug regimen dolutegravir/lamivudine is as effective as the three-drug regimen dolutegravir plus tenofovir ...

More than 40 years have passed since the CDC reported the first cases of HIV in the United States. In that time, we’ve ...

Brian Zanoni, MD, MPH, discusses forecasts that suggest declining global HIV rates but persistent gaps in care and funding.

Swiss study shows 60% of migrant HIV diagnoses are made post-arrival, challenging assumptions about when infections actually ...

Protecting public health abroad benefits Americans. In a globalized world, diseases and their social and economic impacts do ...

The Trump administration’s new global HIV prevention strategy prioritizes preventing mother-to-child HIV transmission. About ...

The findings confirm that allosteric inhibition of integrase is clinically viable, validating a new antiviral drug class.

Viral infections, including HIV and influenza, are associated with an increased risk of cardiovascular disease, including coronary heart disease and stroke.

Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term. Researchers at ...